Abstract
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system in which immune mechanisms appear to be an important component of the pathophysiology. Although the clinical manifestations are variable, a subset of patients develops a progressive clinical course associated with marked neurologic impairment and significant morbidity. BMT has been proposed as a treatment for such patients based on preclinical data as well as clinical observations in other autoimmune diseases. We report clinical and MRI findings in an MS patient, later diagnosed with CML, and treated with an allogeneic BMT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McAllister, L., Beatty, P. & Rose, J. Allogeneic bone marrow transplant for chronic myelogenous leukemia in a patient with multiple sclerosis. Bone Marrow Transplant 19, 395–397 (1997). https://doi.org/10.1038/sj.bmt.1700666
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1700666
Keywords
This article is cited by
-
Allogene hämatopoetische Stammzelltransplantation
Zeitschrift für Rheumatologie (2016)
-
Hematopoietic Stem Cell Therapy for Multiple Sclerosis: Top 10 Lessons Learned
Neurotherapeutics (2013)
-
Hematopoietic SCT for the treatment of multiple sclerosis
Bone Marrow Transplantation (2010)
-
Aggressive multiple sclerosis—is there a role for stem cell transplantation?
Journal of Neurology (2005)